NCT05059587View on ClinicalTrials.gov

Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Glabellar Lines

PHASE3CompletedINTERVENTIONAL
Enrollment

318

Participants

Timeline

Start Date

August 30, 2021

Primary Completion Date

December 29, 2021

Study Completion Date

March 29, 2022

Conditions
Glabellar Frown Lines
Interventions
DRUG

MBA-P01

MBA-P01 will be injected into the Glabellar line.

DRUG

BOTOX

Botox will be injected into the Glabellar line.

Trial Locations (1)

156-755

Chung-Ang Univ. Hospital, Seoul

All Listed Sponsors
lead

Medytox Korea

INDUSTRY

NCT05059587 - Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Glabellar Lines | Biotech Hunter | Biotech Hunter